GlaxoSmithKline News and Research

RSS

Weekly Digest releases report on investment opportunities in connection with the H1N1 outbreak

Weekly Digest (http://www.bullmarket.com/digest), a free investment research publication, announced the publication of a special report on investment opportunities in connection with the H1N1 "Swine Flu" Outbreak, including updated outlooks for GlaxoSmithKline, Sanofi-Aventis, Novartis, Baxter International, Roche Holding and several others.

21 Oct 2009

AFFiRiS reports encouraging results from clinical studies of its two Alzheimer's vaccines

AFFiRiS AG today announced that the primary endpoints have been met for the Phase I clinical studies of its two Alzheimer's vaccines AD01 and AD02, which demonstrated favourable safety and tolerability profiles. These results trigger a 10 million EUR milestone payment from licensee GlaxoSmithKline Biologicals.

21 Oct 2009

Also in Global Health News: Cholera in Zimbabwe; personal computers; medical 'outliers'; rain in Kenya; generic drugs

A cholera outbreak in Zimbabwe has infected more than 100, resulting in five deaths, state media said Tuesday, Reuters reports, "raising fears of a repeat of last year's epidemic that claimed more than 4,000 lives.

21 Oct 2009

Tarsa Therapeutics receives license for Phase III oral calcitonin program

Unigene Laboratories, Inc. and Tarsa Therapeutics, Inc. today announced that Unigene has licensed its Phase III oral calcitonin program to Tarsa, a new company formed by a syndicate of three venture capital funds specializing in the life sciences: MVM Life Science Partners, Quaker BioVentures and Novo A/S.

20 Oct 2009

GlaxoSmithKline to allow Apotex continue manufacturing their drug in Rwanda

GlaxoSmithKline Inc. (GSK) As part of its broad commitment to improving access to medicines and its ongoing support for Canada's Access to Medicines Regime (CAMR), GlaxoSmithKline confirms it will not object - through CAMR - to allow Canadian company (Apotex) to continue manufacturing their drug for the treatment of HIV/AIDS in Rwanda.

20 Oct 2009

Potential hazards of H1N1 vaccine and seasonal flu shot not disclosed, say protesters

As millions of Americans remain concerned about government-recommended flu shots, dozens of citizens dressed in full haz-mat suits will gather Wednesday, October 21, at the entrance to the Centers For Disease Control (CDC) to greet arriving members of the Advisory Committee on Immunization Practices.

20 Oct 2009

Fluarix seasonal influenza vaccine approved by the FDA

The U.S. Food and Drug Administration today approved use of the seasonal influenza vaccine Fluarix for children ages 3 years to 17 years. Previously, this vaccine, which contains inactivated (killed) influenza A and B viruses, had been approved for use in adults, ages 18 years and older.

20 Oct 2009

GlaxoSmithKline may see increased sales of Relenza during the A/H1N1 2009 pandemic

Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that during the A/H1N1 (swine flu) pandemic, GlaxoSmithKline could see its Relenza sales increase if Tamiflu-resistant strains of the virus spread. GlaxoSmithKline recently signed A/H1N1 2009 vaccine contracts with various governments for more than $3 billion and is donating supplies to less wealthy nations, ensuring that the company strikes a balance between profit and public health concerns.

20 Oct 2009

Human Genome Sciences and GlaxoSmithKline to present Phase 3 trial results of BENLYSTA

Human Genome Sciences, Inc. and GlaxoSmithKline PLC (GSK) today announced the full presentation of results from BLISS-52, the first of two pivotal Phase 3 trials of BENLYSTA™ (belimumab) in seropositive patients with systemic lupus erythematosus (SLE).

20 Oct 2009

FDA approves new oral medication for renal cell carcinoma

The U.S. Food and Drug Administration today approved Votrient (pazopanib), the sixth drug to be approved for kidney cancer since 2005.

20 Oct 2009

FDA approves GlaxoSmithKline Biologicals' Cervarix for prevention of cervical cancer

The FDA today approved Cervarix, a new vaccine to prevent cervical cancer and precancerous lesions caused by human papillomavirus (HPV) types 16 and 18. The vaccine is approved for use in girls and women ages 10 years through 25 years.

19 Oct 2009

GlaxoSmithKline receives FDA approval for cervical cancer vaccine

GlaxoSmithKline announced today that the U.S. Food and Drug Administration (FDA) has approved CERVARIX® [Human papillomavirus bivalent (types 16 and 18) vaccine, recombinant] for the prevention of cervical pre-cancers and cervical cancer associated with oncogenic human papillomavirus (HPV) types 16 and 18 for use in girls and young women (aged 10-25).

19 Oct 2009

Breathe Right "Extra" to help consumers sleep better at night

While many of us will never know the feeling of playing in a professional football game, we all should know the feeling of getting a good night's sleep. However, many adults suffer from night-time congestion, a good night's sleep can be as elusive as a speedy running back - until now.

15 Oct 2009

IQPC to hold the 8th Annual Polymorphism & Crystallization Scientific Forum

Organized by IQPC, the 8th Annual Polymorphism & Crystallization Scientific Forum will be held October 26-28, 2009 at the Hub Cira Center in Philadelphia, PA (www.polymorphismforum.com).

From IQPC Ltd 15 Oct 2009

Low-, middle-income countries could receive donated H1N1 vaccine shipments by November, WHO says

About 100 low- and middle-income countries could receive donated shipments of the H1N1 (swine flu) vaccine as early as November, Marie-Paule Kieny, of the WHO, told journalists Monday, Agence France-Presse reports. "Dozens of millions of doses are being lined up following offers from pharmaceutical companies," including Sanofi-Aventis, GlaxoSmithKline and MedImmune, as well as a coalition of developed nations "that have pledged to release 10 percent of their vaccine purchases for poor nations," the news service writes (10/12).

12 Oct 2009

Wake Forest University School of Medicine honours researchers

Wake Forest University School of Medicine honored eight of its researchers with awards for excellence at the 13th Annual Research Awards Day Oct. 1.

12 Oct 2009

GF Capital Private Equity Fund purchases Airborne

Airborne, Inc., maker of dietary supplements that support immune health, today announced that it has been purchased by GF Capital Private Equity Fund, LP, a New York City-based private equity firm. Terms of the deal were not disclosed. Stockton Road Capital, LLC, advised and partnered with GF Capital with respect to this investment.

12 Oct 2009

FDA Advisory Committee approves use of Selzentry tablets in combination with HIV therapy

Pfizer Inc. announced today that the U.S. Food and Drug Administration’s (FDA) Antiviral Drugs Advisory Committee voted (10 to 4) to recommend the approval of Selzentry (maraviroc) tablets for use in treatment-naïve adult patients with CCR5-tropic HIV-1 virus as part of combination therapy.

9 Oct 2009

NIAID awards $60M for research contracts to discover new adjuvants

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has awarded six new research contracts to discover and characterize novel adjuvants, substances that can be added to vaccines to enhance the protective immune response they induce.

9 Oct 2009

GSK and USPTO file joint motion to dismiss litigation over final regulations

GlaxoSmithKline (NYSE: GSK) today announced that it has reached agreement with the United States Patent and Trademark Office (USPTO) to join the USPTO's motion to dismiss its litigation over Final Regulations published in August 2007 (Triantafyllos Tafas and SmithKline Beecham Corporation, SmithKline Beecham PLC and Glaxo Group Limited vs. David J. Kappos and the United States Patent and Trademark Office).

9 Oct 2009

GlaxoSmithKline News and Research

Weekly Digest releases report on investment opportunities in connection with the H1N1 outbreak

AFFiRiS reports encouraging results from clinical studies of its two Alzheimer's vaccines

Also in Global Health News: Cholera in Zimbabwe; personal computers; medical 'outliers'; rain in Kenya; generic drugs

Tarsa Therapeutics receives license for Phase III oral calcitonin program

GlaxoSmithKline to allow Apotex continue manufacturing their drug in Rwanda

Potential hazards of H1N1 vaccine and seasonal flu shot not disclosed, say protesters

Fluarix seasonal influenza vaccine approved by the FDA

GlaxoSmithKline may see increased sales of Relenza during the A/H1N1 2009 pandemic

Human Genome Sciences and GlaxoSmithKline to present Phase 3 trial results of BENLYSTA

FDA approves new oral medication for renal cell carcinoma

FDA approves GlaxoSmithKline Biologicals' Cervarix for prevention of cervical cancer

GlaxoSmithKline receives FDA approval for cervical cancer vaccine

Breathe Right "Extra" to help consumers sleep better at night

IQPC to hold the 8th Annual Polymorphism & Crystallization Scientific Forum

Low-, middle-income countries could receive donated H1N1 vaccine shipments by November, WHO says

Wake Forest University School of Medicine honours researchers

GF Capital Private Equity Fund purchases Airborne

FDA Advisory Committee approves use of Selzentry tablets in combination with HIV therapy

NIAID awards $60M for research contracts to discover new adjuvants

GSK and USPTO file joint motion to dismiss litigation over final regulations

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News